AHL
MDGL icon

Abel Hall LLC’s Madrigal Pharmaceuticals MDGL Stock Holding History

Abel Hall LLC’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$665K Buy
1,271
+561
+79% +$268K 0.14% 126
2025
Q4 		$413K Buy
710
+120
+20% +$61.3K 0.1% 221
2025
Q3 		$271K Buy
+590
New +$220K 0.11% 196

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Abel Hall LLC's MDGL Position: Q1 2026 in Review

Abel Hall LLC increased its Madrigal Pharmaceuticals (MDGL) stake by 79% in Q1 2026, buying an estimated $268K and bringing the position to 1,271 shares worth $665K. The position accounts for 0.14% of the portfolio, ranked #126.

Abel Hall LLC first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Abel Hall LLC held 1,271 shares of Madrigal Pharmaceuticals worth $665K as of Q1 2026.
  • Abel Hall LLC bought 561 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $268K.
  • Madrigal Pharmaceuticals made up 0.14% of Abel Hall LLC's portfolio in Q1 2026, its #126 holding.
  • Abel Hall LLC first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.